Simplification of Excipient Solution for Implanting Candidate Human H9-scNSC Cell Line for Spinal Cord Injury

We are currently developing a clinical cell candidate, spinalized NSCs derived from the H9 human embryonic stem cell line, for a spinal cord injury. Our current composition consists of a fibrin matrix and three growth factors (BDNF, FGF2, VEGF) and a small molecule inhibitor of apoptosis, MDL 28170. This award has systemically determined the necessity for these growth factors and MDL 28170 to support cell graft survival within the lesion cavity and neuronal differentiation.